Disease Status Prediction on ADNI TADPOLE challenge (test)
84.8AccuracyGKD
Evaluation results
| Method | Links | |||||
|---|---|---|---|---|---|---|
| GKDGraph modality availability in testing phase=Not available2021.04 | 84.8 | — | — | 71 | 58.7 | |
| NeuroPathXvalidation=10-fold cross-validation2025.08 | 82.7 | 73.3 | 88.4 | 88 | — | |
| SurvPATHvalidation=10-fold cross-validation2025.08 | 81.8 | 86.7 | 78.7 | 90.8 | — | |
| G-MINDvalidation=10-fold cross-validation2025.08 | 80 | 83.8 | 77.6 | 89.7 | — | |
| DNN-JFCGraph modality availability in testing phase=Not available2021.04 | 79.6 | — | — | 66.2 | 53 | |
| EV-GCNGraph modality availability in testing phase=Not available2021.04 | 76.6 | — | — | 62.9 | 51.4 | |
| Parisot et. alGraph modality availability in testing phase=Not available2021.04 | 76.3 | — | — | 61.9 | 51.2 | |
| NeuroPathX w/o L_spvalidation=10-fold cross-validation, ablation=removed sparsity loss2025.08 | 75.8 | 80 | 73.1 | 85.8 | — | |
| NeuroPathX w/o L_pathvalidation=10-fold cross-validation, ablation=removed pathway similarity loss2025.08 | 74.6 | 78.1 | 72.4 | 85.6 | — | |
| DNNGraph modality availability in testing phase=Not available2021.04 | 72.2 | — | — | 69.5 | 52.3 | |
| Abraham et. alGraph modality availability in testing phase=Not available2021.04 | 60.2 | — | — | 62.3 | 45.3 | |
| CCAvalidation=10-fold cross-validation2025.08 | 59.2 | 24.2 | 81 | 52.6 | — |